| Similar Articles |
|---|
 |
The Motley Fool
November 29, 2011
Rex Moore |
10 Great Values in Pharma and Biotech How to avoid the low-growth, high-risk value trap.   |
The Motley Fool
April 21, 2011
Rex Moore |
Top 10 Values in Health Care Here are the 10 health care equipment and services stocks with the lowest forward price-to-earnings multiples. |
The Motley Fool
August 6, 2010
Rex Moore |
The 7 Best Values in Telecom Low multiples plus low risk equals compelling value. |
The Motley Fool
August 31, 2010
Rex Moore |
The 10 Best Values in Tech Hardware Avoiding the high-risk, no-growth trap. |
The Motley Fool
August 27, 2010
Rex Moore |
The 10 Best Values in Software Low multiples plus low risk equals compelling value in these software stocks. |
The Motley Fool
May 4, 2011
Rex Moore |
Top 10 Values in the Industrial Sector Here are the 10 stocks with the lowest forward price-to-earnings multiples in the industrial sector. |
The Motley Fool
August 24, 2010
Rex Moore |
The 10 Most Undervalued Utilities Of the 17 companies passing the screen, here are the 10 with the lowest forward price-to-earnings multiples |
The Motley Fool
July 18, 2011
Rex Moore |
Top 10 Values in a Materials World We're looking for companies with low price-to-earnings multiples, but also a relatively low amount of risk. Here are ten. |
The Motley Fool
August 4, 2010
Rex Moore |
The 15 Best Values in Health Care Low multiples plus low risk equals compelling value. |
The Motley Fool
June 6, 2011
Rex Moore |
Top 10 Values in Materials How to avoid the low-growth, high-risk value trap. |
The Motley Fool
October 20, 2010
Rex Moore |
Top 10 Values in Chemicals These are some of the best value plays in the chemicals industry. |
The Motley Fool
August 20, 2010
Rex Moore |
The Top 10 Values in Consumer Durables How to identify the real value stocks. |
The Motley Fool
December 16, 2010
Rex Moore |
Best Values in Oil and Gas Avoiding the high-risk, no-growth trap. |
The Motley Fool
August 2, 2010
Rex Moore |
The 15 Best Values in Energy Low multiples plus low risk equals compelling value. |
The Motley Fool
August 5, 2010
Rex Moore |
The 15 Best Industrial Values Low multiples plus low risk equals compelling value. |
The Motley Fool
September 2, 2010
Rex Moore |
The 10 Best Semiconductor Values Our screen today will cover the best value plays in the semiconductors and semiconductor equipment industry. |
The Motley Fool
August 23, 2010
Rex Moore |
The 15 Best Values in Materials Low multiples plus low risk equals compelling value. |
The Motley Fool
July 28, 2010
Rex Moore |
The 20 Best Value Stocks in Tech Low multiples plus low risk equals compelling value in the technology and telecom sectors. |
The Motley Fool
January 12, 2011
Rex Moore |
Top Values in Food and Staples Retailing For a company to be truly undervalued it needs to be a mismatch: a low price-to-earnings ratio without the stigma of high risk or poor growth. These retailers fit that bill. |
The Motley Fool
August 16, 2010
Rex Moore |
The 15 Best Values in Retail Low multiples plus low risk equals compelling value. |
The Motley Fool
July 29, 2010
Rex Moore |
The 15 Best Values in Consumer Staples Low multiples plus low risk equals compelling value. |
The Motley Fool
August 20, 2010 |
Finding Safe Low P/E Stocks NYU professor Aswath Damodaran has surveyed prior research and found that low P/E stocks outperform high P/E stocks by anywhere from 9% to 12% per year on average |
The Motley Fool
October 30, 2010
Anand Chokkavelu |
7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk... |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
The Motley Fool
October 22, 2010
Anand Chokkavelu |
7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential. |
The Motley Fool
October 7, 2011
Rex Moore |
Top 20 Values in International Stocks You need some foreign exposure in your portfolio. Here's where to start. |
The Motley Fool
May 29, 2011
Andrew Tonner |
Does Watson Pharmaceuticals Deserve a Spot in Your Portfolio? Although Watson Pharmaceuticals doesn't look like a stock for your portfolio right now, the search doesn't end here. |
The Motley Fool
October 18, 2010
Anand Chokkavelu |
There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific. |
The Motley Fool
September 11, 2010
Anand Chokkavelu |
How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
The Motley Fool
December 13, 2011 |
A Brief History of Teva Pharmaceutical's Returns The good news is that, at 15 times earnings, Teva shares now look reasonably valued. |
The Motley Fool
June 16, 2004 |
Understanding "Multiples" Understanding multiples can help you evaluate a stock's attractiveness. |
The Motley Fool
January 12, 2007
Elliott Orsillo |
Blue-Light Specials Do low-P/E stocks offer more bang for your buck? |
The Motley Fool
July 30, 2009
Selena Maranjian |
Making Money With Multiples These stats can help you compare companies to find great investments. |
The Motley Fool
October 18, 2011 |
A Brief History of Apple's Returns Apple shares have returned 4,843% over the past decade. How did it get there? |
The Motley Fool
January 5, 2012
Anand Chokkavelu |
Can Varian's Stock Be Cheap by the Numbers? Let's take a look. |
The Motley Fool
September 2, 2010
Anand Chokkavelu |
Is Pfizer Stock Cheap Right Now? If you find Pfizer's numbers compelling, continue your due diligence. |
The Motley Fool
October 20, 2005 |
Understanding "Multiples" Multiples can help you evaluate stock prices. Here's what they mean. |
The Motley Fool
September 3, 2010
Anand Chokkavelu |
Is Microsoft Stock Cheap Right Now? Let's take a look. |
The Motley Fool
September 11, 2010
Anand Chokkavelu |
How Much of a Bargain Is Apple Stock Right Now? What can price multiples, consistency of past earnings, and amount of growth expected tell us about Apple's true value? |
The Motley Fool
September 12, 2010
Anand Chokkavelu |
How Expensive Is Google Stock Right Now? Let's use some carefully chosen metrics to size up Google's true value. |
The Motley Fool
September 10, 2010
Anand Chokkavelu |
How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates. |
The Motley Fool
May 23, 2011
Andrew Tonner |
Does Amgen Deserve a Spot in Your Portfolio? Depending on your assessment of future growth, Amgen could certainly make a nice addition to your portfolio. |
The Motley Fool
September 2, 2010
Anand Chokkavelu |
How Cheap Is General Electric Stock Right Now? Let's use some carefully chosen metrics to size up General Electric's true value. |
The Motley Fool
January 8, 2012
Anand Chokkavelu |
Best Buy's Stock Looks Cheap by the Numbers Let's take a look. |
The Motley Fool
September 7, 2010
Anand Chokkavelu |
How Much of a Bargain Is Frontier Communications Right Now? Let's take a look. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
September 16, 2010
Anand Chokkavelu |
How Cheap Is Brocade by the Numbers? Brocade is 0 for 4 on hitting the ideal targets, but let's see how it compares against some competitors and industry mates. |
The Motley Fool
September 2, 2010
Anand Chokkavelu |
How Much of a Bargain Is Schlumberger Stock Right Now? Over the past five years, Schlumberger has tallied up 5 years of positive earnings and 5 years of positive free cash flow. |
